3-(1,3-Benzodioxol-5-yloxymethyl)piperidine | 245057-78-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并间二氧杂环戊烯类
• 英文名称: 3-(1,3-Benzodioxol-5-yloxymethyl)piperidine
• CAS: 245057-78-7
• 化学式: C₁₃H₁₇NO₃
• mdl: MFCD10022891
• 分子量: 235.283
• InChiKey: OQLZTHULURQAQC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.538
• 拓扑面积：
  39.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(1,3-Benzodioxol-5-yloxymethyl)piperidine 、 2-氯乙酰基-6,7-二甲氧基-1,2,3,4-四氢异喹啉 在 potassium carbonate 作用下， 以 乙腈 为溶剂， 生成 2-[3-(1,3-benzodioxol-5-yloxymethyl)piperidin-1-yl]-1-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethanone
  参考文献：
  名称：

  Synthesis and pharmacological evaluation of piperidinoalkanoyl-1,2,3,4-tetrahydroisoquinoline derivatives as novel specific bradycardic agents

  摘要：

  A series of piperidinoalkanoyl-1,2,3,4-tetrahydroisoquinoline derivatives were synthesized, and their bradycardic activities were investigated in the isolated right atria of guinea pigs and in conscious rats. These efforts identified the achiral compound 2f, which exhibited potent and long-lasting bradycardic activity with minimal effects on mean blood pressure in conscious rats. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.04.031
• 作为产物：
  描述：

  芝麻酚 在 platinum(IV) oxide 氢气 、 potassium carbonate 、 溶剂黄146 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 3-(1,3-Benzodioxol-5-yloxymethyl)piperidine
  参考文献：
  名称：

  Synthesis and pharmacological evaluation of piperidinoalkanoyl-1,2,3,4-tetrahydroisoquinoline derivatives as novel specific bradycardic agents

  摘要：

  A series of piperidinoalkanoyl-1,2,3,4-tetrahydroisoquinoline derivatives were synthesized, and their bradycardic activities were investigated in the isolated right atria of guinea pigs and in conscious rats. These efforts identified the achiral compound 2f, which exhibited potent and long-lasting bradycardic activity with minimal effects on mean blood pressure in conscious rats. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.04.031

文献信息

• Synthesis and evaluation of PSSRI-based inhibitors of Staphylococcus aureus multidrug efflux pumps
  作者：Nadezhda German、Glenn W. Kaatz、Robert J. Kerns

  DOI：10.1016/j.bmcl.2008.01.014

  日期：2008.2

  Phenylpiperidine selective serotonin reuptake inhibitors (PSSRIs) block the function of selected multidrug efflux pumps of Staphylococcus aureus. In this study PSSRI-based piperidine derivatives were prepared, evaluated for inhibition of two multidrug resistance (MDR)-conferring efflux pump systems, and tested for potentiation of antimicrobial activity of antibacterial efflux pump substrates. It is demonstrated that

  苯哌啶选择性5-羟色胺再摄取抑制剂（PSSRIs）阻止了金黄色葡萄球菌的选定多药外排泵的功能。在这项研究中，制备了基于PSSRI的哌啶衍生物，评估了对两种具有多重耐药性（MDR）的外排泵系统的抑制作用，并测试了抗菌外排泵底物的抗菌活性。证明基于PSSRI的外排泵抑制剂（EPI）的4-苯基部分不是抑制NorA和MepA MDR外排泵的绝对结构要求。通过用芳基烯烃和芳基硫醚部分取代PSSRIs的3位上的芳氧基甲基取代基来维持或增强外排抑制的能力。新型3-芳基哌啶EPI可显着提高针对S菌株的底物抗生素活性。
• LIGANDS FOR MONOAMINE RECEPTORS AND TRANSPORTERS, AND METHODS OF USE THEREOF
  申请人：Aquila Brian M.

  公开号：US20090258901A1

  公开（公告）日：2009-10-15

  One aspect of the present invention relates to heterocyclic compounds. A second aspect of the present invention relates to the use of the heterocyclic compounds as ligands for various mammalian cellular receptors, including dopamine, serotonin, or norepinephrine transporters. The compounds of the present invention will find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, schizophrenia, Parkinson's disease, inflammatory pain, neuropathic pain, Lesche-Nyhane disease, Wilson's disease, and Tourette's syndrome. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the heterocyclic compounds, and the screening of those libraries for biological activity, e.g., in assays based on dopamine transporters.

  本发明的一个方面涉及杂环化合物。本发明的第二个方面涉及将杂环化合物用作各种哺乳动物细胞受体的配体，包括多巴胺、血清素或去甲肾上腺素转运体。本发明的化合物将用于治疗许多影响哺乳动物的疾病、状况和疾病，包括但不限于成瘾、焦虑、抑郁、性功能障碍、高血压、偏头痛、阿尔茨海默病、肥胖症、呕吐、精神病、精神分裂症、帕金森病、炎性疼痛、神经痛、Lesche-Nyhane病、威尔逊病和托瑞特综合症。本发明的另一个方面涉及合成杂环化合物的组合库，并对这些库进行生物活性筛选，例如基于多巴胺转运体的测定。
• G PROTEIN-COUPLED RECEPTOR KINASE INHIBITORS AND METHODS FOR USE OF THE SAME
  申请人：The Regents of The University of Michigan

  公开号：EP3313396B1

  公开（公告）日：2021-12-15
• US7294637B2
  申请人：——

  公开号：US7294637B2

  公开（公告）日：2007-11-13
• US7517892B2
  申请人：——

  公开号：US7517892B2

  公开（公告）日：2009-04-14